A Small Molecule Binding HMGB1 Inhibits Caspase-11-mediated Lethality in Sepsis

Xiangyu Wang,Zhaozheng Li,Yang Bai,Rui Zhang,Ran Meng,Fangping Chen,Haichao Wang,Timothy R. Billiar,Xianzhong Xiao,Ben Lu,Yiting Tang
DOI: https://doi.org/10.1038/s41419-021-03652-5
2021-01-01
Cell Death and Disease
Abstract:Caspase-11, a cytosolic lipopolysaccharide (LPS) receptor, mediates lethal immune responses and coagulopathy in sepsis, a leading cause of death worldwide with limited therapeutic options. We previously showed that over-activation of caspase-11 is driven by hepatocyte-released high mobility group box 1 (HMGB1), which delivers extracellular LPS into the cytosol of host cells during sepsis. Using a phenotypic screening strategy with recombinant HMGB1 and peritoneal macrophages, we discovered that FeTPPS, a small molecule selectively inhibits HMGB1-mediated caspase-11 activation. The physical interaction between FeTPPS and HMGB1 disrupts the HMGB1-LPS binding and decreases the capacity of HMGB1 to induce lysosomal rupture, leading to the diminished cytosolic delivery of LPS. Treatment of FeTPPS significantly attenuates HMGB1- and caspase-11-mediated immune responses, organ damage, and lethality in endotoxemia and bacterial sepsis. These findings shed light on the development of HMGB1-targeting therapeutics for lethal immune disorders and might open a new avenue to treat sepsis.
What problem does this paper attempt to address?